This definition appears very rarely
and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other meanings of ETRA
We have 7 other definitions for ETRA
in our Acronym Attic
Samples in periodicals archive:
Specialists in pharmacology, molecular biology, physiology, cardiovascular medicine, and nephrology in Europe, the US, and Asia cover the pharmacology, molecular biology, and physiology of endothelin in the kidney; the role of endothelin and endothelin receptor antagonists (ERAs) in renal disease, including renal inflammation and hypertension, sickle cell disease, and polycystic kidney disease; and the current state of clinical development of ERA therapy in renal medicine, such as for those with resistant hypertension and hypertension nephropathy, diabetic nephropathy, and nondiabetic chronic kidney disease.
The thematic research being presented at the 2011 ATS Conference provides insights into differential benefit of selective versus non-selective endothelin receptor antagonists in a robust preclinical model of this debilitating disease.
They discuss imaging techniques, exercise testing and hemodynamics, epidemiology, current and future treatments, and the use of endothelin receptor antagonists and gene and stem cell therapy.
Based on the properties of the compound and the results of our Phase 2 trial, we believe ambrisentan's efficacy and safety profile may position it as the best-in-class among endothelin receptor antagonists.
Other endothelin receptor antagonists have been associated with elevations of aminotransferases, hepatotoxicity and cases of liver failure.
Important Safety Information Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Letairis.
Tracleer(R) was the first in a new class of treatments for PAH known as endothelin receptor antagonists.
Therapies currently used for the treatment of PAH include anticoagulants; diuretics; calcium channel blockers; digoxin; prostacyclins; phosphodiesterase inhibitors and endothelin receptor antagonists.